CASPAR: a retrospective cohort study of the high-concentration capsaicin topical system in patients with painful diabetic peripheral neuropathy of the feet
Authors' conclusion
This real-world study in patients with pDPN of the feet demonstrates that ongoing HCCTS treatments continue to improve pain intensity, mood, and QoL, while concomitant medication use decreases. Benefits from treatment were lost following HCCTS discontinuation. These findings emphasize the importance of ongoing treatments to achieve the potential of HCCTS in improving outcomes for patients with pDPN.
Study context
- Population
- Patients with painful DPN of the feet who received ≥1 high-concentration capsaicin topical system (HCCTS) treatment (≈3-month intervals) and contributed data to the German Pain e-Registry (GPeR) for ≥12 months
- Participants
- 365 patients
- Exposure
- Number of HCCTS treatments over 12 months
- Outcome
- Mean 24-hour average pain intensity (API) score, baseline to month 12
- Follow-up
- Baseline to month 12
Methodological detailsnon-interventional, real-world, German Pain e-Registry (GPeR) data
- Non-interventional
- Real-world
- German Pain e-Registry (GPeR) data
Main finding
As reported in the abstract
Four HCCTS: mean average pain intensity (API) 61.4 to 8.8
∆ −52.6
Three HCCTS: mean API 59.3 to 16.7
∆ −42.6
Two HCCTS: mean API 56.3 to 31.9
∆ −24.4
One HCCTS: mean API 57.5 to 51.4
∆ −6.1
Observational data: associations, not effects.
Further findings
Sleep, mood and quality of life (QoL)
- Similar trends as for API
Concomitant pain medication use
- Significant reduction with ongoing HCCTS treatments
Original publication
Composed by AI from the published abstract and checked against it. How Briefs are made →